Search

Blog

We constantly analyse the legislation and regulatory information related to a specific medicine in order to appraise the context in which the company operates

We put all our knowledge into play to anticipate risks and seize every opportunity, but above all to understand the rules of the game and display our creativity with them. We spread material and information proceeding from our investigation into medicines governance and regulatory science. In fact, we deem it necessary to be aware of the complexity of the results of research, regulation and drug policy in order to be able to work in a cultural ecosystem aiming both at promoting research outcomes that are useful to patients and at encouraging politicians to protect people’s health. The wider the knowledge of each interest group, the greater their ability to interact and achieve transparency of procedures and health protection.

  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
All
  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
1st OsMed Report on Parallel Import (IP) and Export of Medicines for Human Use by AIFA

1st OsMed Report on Parallel Import (IP) and Export of Medicines for Human Use by AIFA

I° Rapporto OsMed sull’importazione parallela (IP) ed esportazione dei medicinali per uso umano di AIFA Puoi rivederlo qui https://lnkd.in/dRgRGUV Nella presentazione di ...
Read more "

New application form for listing of medicines under Law 648/96

AIFA ha pubblicato un nuovo modulo per la richiesta di inserimento di medicinali nell’elenco ai sensi della legge 648/96; si evincono alcune ...
Read more "

Scientific Committee on Post-Market Surveillance of COVID-19 Vaccines (CSV-Covid19)

L’AIFA, il 14 dicembre 2020, ha costituito un comitato scientifico per la sorveglianza post-marketing dei vaccini COVID-19 (CSV-Covid19). Il CSV-Covid19 rimarrà in ...
Read more "

Coronavirus: new set-up for the Scientific Technical Committee. Reduction in the number of members and new professionalism

Con il Decreto del Capo Dipartimento della Protezione civile n. 371 del 5 febbraio 2020, è stato istituito il Comitato Tecnico Scientifico ...
Read more "

Working Group for the Coordination of the National Antimicrobial Resistance Strategy

Tornano gli appunti di Pharma Value con l’aggiornamento della composizione del Gruppo di lavoro per il coordinamento della strategia nazionale di contrasto ...
Read more "
COVID19 Technical Scientific Committee

Redefinition of the Scientific Technical Committee (STC) COVID-19

Con ordinanza del Capo Dipartimento della Protezione civile n. 663 del 18 aprile 2020 e delle successive ordinanze: n. 673 del 15 ...
Read more "

New Criteria and Procedures for the negotiation of prices of medicines reimbursed by the Italian Health Service

On 30 December 2020 AIFA approved the document containing the provisions required by art. 2 of Ministerial Decree of 2 August 2019, ...
Read more "

AIFA National Report 2019 'The use of antibiotics in Italy'

Il 29 Dicembre è stato presentato il Rapporto Nazionale 2019 “L’uso degli antibiotici in Italia” il quale fornisce dati e analisi sull’andamento ...
Read more "

Highlights on the AIFA Pricing Guidelines

Sono state finalmente pubblicate le Linee Guida AIFA per la compilazione del dossier a supporto della domanda di rimborsabilità e prezzo di ...
Read more "
en_GB